Caraco V. Novo Nordisk — A Divided Supreme Court

Law360, New York (December 7, 2011, 1:35 PM EST) -- On Dec. 5, 2011, the U.S. Supreme Court held oral argument in the first patent-related case of the 2011-12 term — Caraco Pharmaceuticals Laboratories Ltd. v. Novo Nordisk A/S, Case No. 10-844. Although some commentators predicted an easy win for Caraco, the oral argument painted a picture of a court genuinely split over when a generic drug maker can file a counterclaim under Section 355 of the Hatch-Waxman Act to force the U.S. Food and Drug Administration or a new drug application (NDA) holder to correct the accuracy of patent use codes listed by the FDA in the Orange Book....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!